Two Lymphoma Foundations Merge to Form the Lymphoma Research Foundation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 4
Volume 11
Issue 4

LOS ANGELES-The Lymphoma Research Foundation of America (LRFA) and the New York-based Cure For Lymphoma Foundation (CFL) have merged to become the Lymphoma Research Foundation (LRF), the nation’s only organization dedicated solely to funding lymphoma research and providing information, education, and support to all those touched by the disease.

LOS ANGELES—The Lymphoma Research Foundation of America (LRFA) and the New York-based Cure For Lymphoma Foundation (CFL) have merged to become the Lymphoma Research Foundation (LRF), the nation’s only organization dedicated solely to funding lymphoma research and providing information, education, and support to all those touched by the disease.

By reducing duplicative administrative and program costs, the new foundation expects to be able to enhance its services to patients, caregivers, and health care professionals.

LRFA and CFL have a collective 17 years of experience and have funded more than $7 million in lymphoma research. The new LRF will continue to fund basic, translational, and clinical research projects at the fellow and junior faculty levels.

The new foundation has offices in Los Angeles, focusing on patient services and educational and support programs, and New York, focusing on research grants, public policy and advocacy, finance and development, and professional education. More information is available online at www.lymphoma.org.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.